Skip to main content

Table 4 SVR12 valuesa for clinical-trial regimens with and without RBV in patients who were (i) cirrhotic or non-cirrhoticb, (ii) treatment-experienced or -naïve, or (iii) HIV-positive or -negative

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Regimen

SVR12% [95% CI]

Cirrhotic

Non-cirrhotic

Treatment-experienced

Treatment-naïve

HIV-positive

HIV-negative

DCV + SOF containing regimens

 DCV + SOF

+RBV

87.3

[74.1, 96.9]

n = 42

95.5

[76.0, 100.0]

n = 16

NR

100.0

[68.3, 100.0]

n = 5

NR

100.0

[68.3, 100.0]

n = 5

−RBV

62.5 [44.9, 78.6]

n = 32

97.4

[93.2, 99.8]

n = 136

90.8

[79.6, 98.4]

n = 55

91.7

[87.9, 94.9]

n = 328

92.3

[69.9, 100.0]

n = 13

89.6

[84.1, 94.2]

n = 165

GZR containing regimens

 GZR + EBR + MK-3682

+RBV

NR

NR

NR

NR

NR

NR

−RBV

NR

88.4

[76.8, 96.5]

n = 43

NR

88.4

[76.8, 96.5]

n = 43

NR

88.4

[76.8, 96.5]

n = 43

 GZR + RZR + MK-3682

+RBV

NR

NR

NR

NR

NR

NR

−RBV

NR

93.0

[83.1, 99.1]

n = 43

NR

93.0

[83.1, 99.1]

n = 43

NR

93.0

[83.1, 99.1]

n = 43

 GZR + EBR + SOF

+RBV

NR

NR

NR

NR

NR

NR

−RBV

90.9

[65.0, 100.0]

n = 11

96.6

[85.8, 100.0]

n = 29

NR

95.0

[85.5, 99.9]

n = 40

NR

95.0

[85.5, 99.9]

n = 40

LDV containing regimens

 LDV + SOF

+RBV

79.1

[68.3, 88.3]

n = 67

93.2

[87.0, 97.7]

n = 98

82.0

[70.0, 91.6]

n = 50

91.3

[87.3, 94.7]

n = 246

NR

88.2

[79.8, 94.6]

n = 76

−RBV

NR

NR

NR

64.0

[44.0, 81.9]

n = 25

NR

64.0

[44.0, 81.9]

n = 25

OBV containing regimens

 OBV + PTV/r

+RBV

NR

50.0

[18.9, 81.1]

n = 10

NR

50.0

[18.9, 81.1]

n = 10

NR

50.0

[18.9, 81.1]

n = 10

−RBV

NR

9.1

[0.0, 35.0]

n = 11

NR

9.1

[0.0, 35.0]

n = 11

NR

9.1

[0.0, 35.0]

n = 11

 OBV + PTV/r + SOF

+RBV

NR

90.9

[65.0, 100.0]

n = 11

NR

NR

NR

NR

−RBV

NR

100.0

[81.7, 100.0]

n = 9

NR

NR

NR

NR

PIB containing regimens

 PIB + GLE

+RBV

100.0

[93.0, 100.0]

n = 24

NR

NR

100.0

[93.0, 100.0]

n = 24

NR

100.0

[93.0, 100.0]

n = 24

−RBV

100.0

[93.0, 100.0]

n = 24

94.6

[88.5, 98.7]

n = 89

66.7

[5.9, 100.0]

n = 3

98.0 [92.9, 100.0]

n = 80

NR

97.1 [91.7, 100.0]

n = 83

 PIB + PTV/r

+RBV

NR

90.0

[61.9, 100.0]

n = 10

NR

90.0

[61.9, 100.0]

n = 10

NR

90.0

[61.9, 100.0]

n = 10

−RBV

NR

NR

NR

NR

NR

NR

VEL containing regimens

 VEL100 + SOF

+RBV

93.3

[82.2, 99.7]

n = 39

100.0

[93.5, 100.0]

n = 26

98.1

[91.9, 100.0]

n = 52

NR

NR

98.1

[91.9, 100.0]

n = 52

−RBV

84.7

[77.8, 90.6]

n = 132

97.6

[95.1, 99.4]

n = 278

92.1

[86.4, 96.4]

n = 124

97.3

[94.6, 99.2]

n = 260

91.7

[67.6, 100.0]

n = 12

93.9

[87.2, 98.5]

n = 80

 VEL100 + SOF + VOX

+RBV

NR

NR

NR

NR

NR

NR

−RBV

92.9

[83.9, 98.8]

n = 55

100.0

[92.0, 100.0]

n = 21

98.7

[92.7, 100.0]

n = 54

94.4

[86.1, 99.4]

n = 57

NR

NR

SOF containing regimens

 SOF

+RBV

70.1

[65.9, 74.0]

n = 540

82.8

[80.4, 85.18]

n = 1039

77.2

[73.0, 81.2]

n = 430

81.1

[79.0, 83.1]

n = 1453

80.4

[75.5, 84.8]

n = 283

58.5

[53.2, 63.6]

n = 344

−RBV

NR

NR

NR

NR

NR

NR

Peg-IFN containing regimens

 Peg-IFN

+RBV

43.6

[35.1, 52.4]

n = 140

75.4

[69.3, 81.2]

n = 256

NR

69.1

[67.4, 70.9]

n = 2928

55.3

[43.0, 67.3]

n = 69

64.0

[61.6, 66.4]

n = 1752

−RBV

NR

NR

NR

NR

NR

NR

 Peg-IFN + SOF

+RBV

94.3

[90.0, 97.7]

n = 201

94.0

[87.4, 98.7]

n = 119

70.9

[63.7, 77.7]

n = 170

99.1

[94.8, 100.0]

n = 133

100.0 [30.3, 100.0]

n = 2

83.3

[65.4, 96.0]

n = 24

−RBV

NR

NR

NR

NR

NR

NR

  1. CI confidence interval, DCV daclatasvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, I-Sq I2, LDV, ledipasvir, NR not reported, OBV ombitasvir, Peg-IFN pegylated interferon, PIB pibrentasvir, PTV paritaprevir, RBV ribavirin, r ritonavir, SOF sofosbuvir, RZR ruzasvir, VEL100 velpatasvir 100 mg, VOX voxilaprevir
  2. aWhere SVR12 was not available, SVR24 was used
  3. bCohorts were considered non-cirrhotic if 0% of patients were cirrhotic. Where SVR12 values of 100% are presented, this may be due to clinical trials that were exclusively HIV-positive or -negative, exclusively treatment-experienced or -naïve, or exclusively cirrhotic or non-cirrhotic